Last Updated: September 24, 2026

Genus Lifesciences Company Profile

✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for GENUS LIFESCIENCES

GENUS LIFESCIENCES has eight approved drugs.

There are five US patents protecting GENUS LIFESCIENCES drugs.

Summary for Genus Lifesciences

US Patents:	5
Tradenames:	8
Ingredients:	7
NDAs:	8

Drugs and US Patents for Genus Lifesciences

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016		DISCN	Yes	No	9,539,214	⤷ Start Trial				⤷ Start Trial
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-010	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,406,108	⤷ Start Trial	Y			⤷ Start Trial
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-011	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,406,108	⤷ Start Trial	Y			⤷ Start Trial
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-012	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,231,931	⤷ Start Trial	Y			⤷ Start Trial
Genus Lifesciences	POTASSIUM CHLORIDE	potassium chloride	SOLUTION;ORAL	206814-002	Dec 22, 2014	AA	RX	Yes	Yes	12,539,314	⤷ Start Trial	Y			⤷ Start Trial
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-004	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,231,931	⤷ Start Trial	Y			⤷ Start Trial
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-012	Jun 6, 2003	AB1,AB2,AB3,AB4	RX	No	No	10,406,108	⤷ Start Trial	Y			⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for Genus Lifesciences

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016	6,926,907	⤷ Start Trial
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016	8,206,741	⤷ Start Trial
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016	9,364,439	⤷ Start Trial
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016	6,926,907	⤷ Start Trial
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016	9,364,439	⤷ Start Trial
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016	8,206,741	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Delayed-release Tablets	81 mg/40 mg	➤ Subscribe	2016-10-14

International Patents for Genus Lifesciences Drugs

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Ukraine	115139	⤷ Start Trial
China	104519888	⤷ Start Trial
Canada	2860231	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2013101897	⤷ Start Trial
Eurasian Patent Organization	201491285	⤷ Start Trial
Eurasian Patent Organization	028049	⤷ Start Trial
Brazil	112014016085	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for Genus Lifesciences Drugs

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1499331	SPC/GB13/034	United Kingdom	⤷ Start Trial	PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
1718641	SPC/GB12/028	United Kingdom	⤷ Start Trial	PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTERED: UK EU/1/11/734/001-011 20111209
0733366	SPC/GB98/031	United Kingdom	⤷ Start Trial	PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
1441735	SPC/GB08/020	United Kingdom	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; REGISTERED: UK EU/1/07/436/001 20080102
3141251	301099	Netherlands	⤷ Start Trial	PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016
1441735	08C0026	France	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
1441735	2008/010	Ireland	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.